Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage III non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Journal Article
| Authors: | Kostakoglu, L.; Schoder, H.; Johnson, J. L.; Hall, N. C.; Schwartz, L. H.; Straus, D. J.; LaCasce, A. S.; Jung, S. H.; Bartlett, N. L.; Canellos, G. P.; Cheson, B. D. |
| Article Title: | Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage III non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? |
| Abstract: | Our objective was to validate the International Harmonization Project (IHP) positron emission tomography (PET) response criteria and correlate with the Deauville criteria and diagnostic computed tomography-based (dCT) lesion size changes. All patients were recruited prospectively to the Cancer and Leukemia Group B (CALGB) 50203 trial for the treatment of stage I-II, non-bulky Hodgkin lymphoma (HL). [ 18F]Fluorodeoxyglucose (FDG) PET and dCT were performed at baseline and after two doxorubicin, vinblastine and gemcitabine (AVG) cycles (PET-2, dCT-2) in 88 patients. IHP and Deauville criteria and percent decrease in the sum of the products of the perpendicular diameters (%SPPD) after two cycles were correlated with progression-free survival (PFS). After a median follow-up of 3.3 years, 23.9% of patients relapsed/progressed (3-year PFS 77%). By IHP, the 2-year PFS was 88% and 54% for PET-2 negative and positive groups, respectively (p = 0.0009). Similar results were obtained for Deauville criteria. In a univariate analysis, PET-2 predicted PFS better than %SPPD, and in a combinatorial analysis, in the PET-2 positive group, a negative dCT-2 increased PFS by 27-35%. However, some confidence intervals were large due to small sample sizes. In conclusion, IHP and Deauville criteria-based interpretation of PET-2 was strongly associated with 2-year PFS. The combined analysis of PET-2 with dCT-2 suggested a better predictive value for PFS compared to either test alone. Further studies are under way to confirm these findings. © 2012 Informa UK, Ltd. |
| Keywords: | therapy response; interim pet/ct; lymphoma and hodgkin disease |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 53 |
| Issue: | 11 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2012-11-01 |
| Start Page: | 2143 |
| End Page: | 2150 |
| Language: | English |
| DOI: | 10.3109/10428194.2012.676173 |
| PROVIDER: | scopus |
| PUBMED: | 22421007 |
| PMCID: | PMC5751716 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 2 November 2012" - "CODEN: LELYE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work